Futura Medical Share Discussion Threads

[lbo] 12/9/2022 14:45

LOL Yes do the maths! Even if an alcohol and water gel does somehow manage to capture 5% of the global ED market. It will be the established brands in the lubricants/arousal gel market that see the real revenue. Not Futura. https://futuramedical.com/media/2187/admission_doc.pdf a The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[j777j] 12/9/2022 14:43

At just one time per week that is revenues of £32 million A WEEK.Think about it !

[j777j] 12/9/2022 14:25

Oh how funny people can watch the utter desperation of lbo.Business is dynamic. Lbo's increasingly frequent postings simply highlight his irrelevance. 300 million men 217p wholesale priceEven a tiny 5% market share would value futura in the £££'sDo the maths.

[lbo] 12/9/2022 13:43

Long standing shareholders learned from Futura what clauses have been in previous deals that favour their partners. Just to get the deals signed and announced. But allows the partners to never have to launch or if they do launch never have to pay any real royalties. There was Zero value to shareholders in every so called contract FUM have signed since 2003. And even just allow partners to hand back the rights with no real penalties after sitting on the rights and running down any patents eg Reckitt and CSD500. Or what shareholders remember the deal with Kabey who was supposedly ‘well established’ group and ‘exciting times’ were ahead! Yet Kabey itself no longer even exists? LOL




a agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product.

The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[j777j] 12/9/2022 13:35

Launch across the UK and EU imminentUnstoppable now

[lbo] 12/9/2022 13:31

Here is the Med3000 patent application! LOLhttps://patents.google.com/patent/WO2021116651A1/enThe composition of the invention contained: ethanol: 33%; water: 35%; glycerol: 24%; propylene glycol: 6%; Carbopol® Ultrez 10: 1%. pH was adjusted to 5.25 with potassium hydroxide solution. The ethanol used in the manufacture of the composition was absolute ethanol (i.e. 100% ethanol free from water) such that the final composition contained 33% of pure ethanol. If a lower grade of ethanol was used which contained impurity amounts of water (e.g. 96% ethanol), then the amount used would have to be adjusted to ensure the final composition contained the correct amount of the components, i.e. 33% pure ethanol and 35% water.https://saraluna.de/Kama-Sutra-Intensify-Plus-Female-Arousal-Gel-Cooling-15-ml_1Kama Sutra Intensify Plus Female Arousal Gel Cooling 15 mlIngredients: Water, Propylene Glycol, Denatured Alcohol

[lbo] 12/9/2022 13:29

LOL

That anyone including Reckitt can copy and sell their own water, glycol and alcohol gel that also causes evaporative cooling






The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.

[j777j] 12/9/2022 13:13

Very exciting times ahead300 million men suffer from ED globallyAt 217p per unit wholesale it doesn't take rocket science to see futura will be worth £££'s a share

[lbo] 12/9/2022 11:41

Not short. But anyone who went short from March 2021 is still seriously in the money even if they hadn’t covered when it was down below 30p! LOL

Suspect shorters would be looking to again build short positions on the back of any further share price strength with the De Novo device registration submission announcement, possibly the ramping even around a test launch online somewhere in the EU/UK. Basically what happened with CSD500 until ultimately the realisation sets in there is no real prospect of any significant revenues especially as similar products are launched and ultimately the Med3000 product is deemed a failure. As Liberum said the risks have only moved from regulatory to execution risk. And their execution of bringing PET500, CSD500 and TPR100 to maktet have all been disasters! Yet Reckit has similar products to each of Futura’s failed products still on the market (KY Duration) (Durex warming/Durex intense condoms) (Nurofen pain gel). They even admitted they can’t take on the likes of Reckitt. And that was with a product that had patent protections and some real clinically proven USPs against standard condoms. Which MED3000 does not have.




‘Futura does not have the marketing or regulatory resources to support the day-to-day requirements in a growing compliance-driven medical device market’

‘the immediate potential for substantial royalties is low in the absence of a large global brand 'carrier' to take the product forward’

[losses] 12/9/2022 11:24

LBO getting shafted by his own shorts here!! Buy up and enjoy the ride to 100

[lbo] 12/9/2022 09:23

I am also very interested to even hear how the De Novo registration is a positive? When its clear that all Futura may have done is create a new regulatory category around arousal gel/lubricants with placebo effect for psychological ED. That others including Reckitt can then just copy via the 510k pathway.



‘This De Novo authorization will also allow subsequent devices of the same type and intended use to come to the market through the 510k pathway, which could enable the devices to get on the market faster.”

De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this De Novo authorization, the FDA is establishing criteria called special controls that define the requirements related to labeling and performance testing. When met, the special controls, in combination with general controls, provide a reasonable assurance of safety and effectiveness for devices of this type. This action also creates a new regulatory classification, which means that subsequent devices of the same type with the same intended use may go through the FDA 510(k) pathway, whereby devices can obtain clearance by demonstrating substantial equivalence to a predicate device

The average length of time for clearance under the traditional 510(k) pathway is 177 days,



‘a company must compare their product to one already cleared by the FDA and provide evidence that their product is substantially equivalent to the previously cleared (legally marketed) device. To be substantially equivalent, the product must meet criteria for the same intended use, have the same technology or (slightly) different technology but produces similar end results, and be safe and effective. Once pre-market clearance is received from the FDA the device can be distributed commercially immediately’

[lbo] 12/9/2022 09:07

I am very interested in Futura. Have been for years.I am even more interested to get an update on an enforceable patent on something that was clearly already described in research literature!?



The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents’



There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products




A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.

[cjpaul] 11/9/2022 22:30

LBO please do not get me wrong but why do you persist on posting so much information on a share that you clearly have no interest in? Have you lost money on this and are determined to warn off others (assuming your intentions are altruistic) or you are bitter and want to destroy the share. Just curious!!

[j777j] 11/9/2022 22:15

In stores soon folks

[j777j] 10/9/2022 16:24

Oh look at her she has been busy all night and day.Peoplewithnolives.com

[lbo] 10/9/2022 13:28

Another good year and a half for ‘investors’ since Broomrigg started ramping on ADVFN and all over the internet under one of his many multi-IDs! LOL


Broomrigg - 28 Mar 2021 - 06:20:09 - 9211 of 13287

Don't know if this has already been posted but its a good read......

[lbo] 10/9/2022 13:04

Broomrigg/Petroc multi-ID user thanks again for highlighting that the name Eroxon goes all the way back to 2016 when the product was Med2005 and still a pharmaceutical product. But then MED failed its Phase 3 drug trial and also since Oral PDE5I have been allowed make the switch to Pharmacy as they were seen as safe and effective and so become more widely available.

While MED3000 just left as a medical device like any other arousal gel/lubricant and has no active pharmaceutical ingredients. Yet more evidence of misleading and misrepresentation by the rampers! LOL





After Phase III Failure, UK Firm Pushes Placebo to Treat Erectile Dysfunction